OPDP accuses Acorda of improperly marketing MS drug

08/12/2013 | PharmaLive.com

The FDA's Office of Prescription Drug Promotion issued a warning letter to Acorda Therapeutics, accusing it of omitting information on risks, adverse events and contraindications in a newspaper ad for the company's Ampyra multiple sclerosis drug. Acorda was warned last year that a video for the same drug overstated efficacy and minimized risk information.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY